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Abstract
Background: Interleukin-1 beta (IL-1β) and its key regulator, the inflammasome, are suspected to play a role in the
neuroinflammation observed in Alzheimer’s disease (AD); no conclusive data are nevertheless available in AD patients.
Results: mRNA for inflammasome components (NLRP1, NLRP3, PYCARD, caspase 1, 5 and 8) and downstream effectors
(IL-1β, IL-18) was up-regulated in severe and MILD AD. Monocytes co-expressing NLRP3 with caspase 1 or caspase 8
were significantly increased in severe AD alone, whereas those co-expressing NLRP1 and NLRP3 with PYCARD were
augmented in both severe and MILD AD. Activation of the NLRP1 and NLRP3 inflammasomes in AD was confirmed by
confocal microscopy proteins co-localization and by the significantly higher amounts of the pro-inflammatory cytokines
IL-1β and IL-18 being produced by monocytes. In MCI, the expression of NLRP3, but not the one of PYCARD or caspase
1 was increased, indicating that functional inflammasomes are not assembled in these individuals: this was confirmed by
lack of co-localization and of proinflammatory cytokines production.
Conclusions: The activation of at least two different inflammasome complexes explains AD-associated
neuroinflammation. Strategies targeting inflammasome activation could be useful in the therapy of AD.
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Background
Alzheimer’s disease (AD) is a devastating neurodegener-
ative condition characterized by neuronal cell death and
progressive dementia. It is widely accepted that the
extracellular accumulation of amyloid-β (Aβ) in senile
plaques and the formation of neurofibrillary tangles
(NFT) inside neurons as a result of the abnormal phos-
phorylation of the microtubules-associated tau protein
are the main event in the pathogenesis of AD, but the
cellular events leading to plaque-induced neuronal dys-
function are less clear [1]. Inflammatory mediators play
an essential role in the neuroinflammation observed in
AD. In particular interleukin IL-1β is increased in this
condition, and the activation of its key regulator, the
inflammasome, is suspected to be involved in the patho-
genesis of the disease.
The inflammasomes are multiprotein complexes mainly
expressed in myeloid cells that are required for the activa-
tion of caspase 1 protease and the downstream secretion of
two of its substrates, the proinflammatory cytokines IL-1β
and IL-18 [2]. Inflammasome-dependent innate immune
responses are initiated by Nod-like receptors (NLRs), cyto-
plasmic pattern recognition receptors that detect invading
pathogens. NLRs are activated by bacterial, fungal, or viral
molecules that contain pathogen-associated molecular
patterns (PAMPs) or by non-microbial danger signals
(DAMPs) released by damaged cells [3, 4]. NLR activation
leads to their oligomerization to form multiprotein inflam-
masome complexes that serve as platforms for the recruit-
ment, cleavage, and activation of inflammatory caspases.
Four inflammasome complexes (NLRP1, NLRP3, IPAF,
and AIM2) have been identified. These complexes contain
either a specific NLR family protein or AIM2, as well as
the PYCARD and/or Cardinal adaptor proteins and pro-
caspases-1, 5 and 8 [5, 6]. NLRP3 is the best-characterized
inflammasome; its formation requires multiple steps. In a
priming step, transcriptionally active signalling receptors
induce the NF-kB-dependent induction of NLRP3 itself as
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well as that of the caspase 1 substrates of the pro-IL-1β
family [7, 8]. The NLRP3 is, at this stage, in a signalling in-
competent conformation; this is modified upon a second
signal, that will induce the assembly of a multimolecular
complex with PYCARD and caspase 1. Multiple signals,
which are potentially provided in combination, thus trigger
the formation of an active inflammasome, which, in turn,
will stimulate the cleavage and the release of bioactive cy-
tokines including IL-1β and IL-18 [8–18]. Although these
cytokines have a beneficial role in promoting inflammation
and eliminating infectious pathogens, mutations that result
in constitutive inflammasome activation and overproduc-
tion of IL-1β and IL-18 have been linked to inflammatory
and autoimmune disorders [19–21].
The NLRP3 inflammasome complex is suspected to play
a role in AD, as its activation in the microglia by Aβ trig-
gers neuroinflammation [14, 22, 23]. Notably, NLRP3
inflammasome deficiency favours the differentiation of
microglia cells to an M2 (anti-inflammatory) phenotype
and results in a decreased deposition of amyloid-β in the
APP/PSI model of AD; these results reinforce the sugges-
tion that the NLRP3 inflammasome is involved in the
pathogenesis of the disease [24]. No conclusive data are
nevertheless available in patients. To better investigate the
involvement of the inflammasome in AD we performed
in-depth analyses of the expression of genes and proteins
that are part of the inflammasome complex in individuals
with a diagnosis of either AD or mild cognitive impair-
ment (MCI). Results indicated that two different inflam-
masomes, NLRP3 and NLRP1, are activated in AD but
not in individuals with a diangnosis of mild cognitive im-
pairment (MCI).
Results
Up-regulation of inflammasome genes in LPS-primed and
Aβ42-stimulated-monocytes of AD patients
mRNA expression of 84 genes involved in the assembly,
the activation, and the down-stream signalling of inflam-
mosomes was quantified by qPCR in all patients and con-
trols. Data are expressed as the fold change (nFold)
between the results obtained in unstimulated cells and
those obtained upon stimulations of cells with either LPS,
Aβ42 or LPS and Aβ42. In this initial set of experiments,
pools of cells from donors with the same clinical diagnosis
(MCI; MILD AD; severe AD) as well as from HC were
created. Data obtained in LPS-primed and Aβ42−stimu-
lated-monocytes, showed the presence of a significant up-
regulation involving genes, that codify for the proteins that
form the inflammasome in MILD and severe AD, as well
as in MCI. In cells of MCI individuals, though, not all the
genes that are necessary for the assembly of a fully func-
tional inflammasome complex were up-regulated. To
summarize: 1) the expression of NLRP1, NLRP3 and
caspase 8 was greatly increased in all groups of patients
(nFold >10) compared to HC, with no detectable differ-
ences being observed between individuals with a diag-
nosis of AD or MCI; and 2) PYCARD, caspase 1 and
caspase 5 expression was increased in AD (nFold ≥10)
but not in MCI individuals. Only minor differences
were seen between patients and controls in the expres-
sion of these genes in monocytes-stimulated with either
LPS or Aβ42 alone; both stimuli induced IL-1β and IL-6
up-regulation in HC (nFold >10) (Fig. 1).
RT-PCR performed on each individual specimen was
used next to verify the expression of NLRP1, NLRP3,
PYCARD, caspase 1, caspase 5 and caspase 8 in LPS and
Aβ42−stimulated monocytes of patients and HC. Results
of mRNA expression confirmed that: 1) NLRP1, NLRP3
and caspase 8 are significantly increased in AD and MCI
individuals compared to HC (p <0.05), with the highest
values observed in severe AD, and 2) PYCARD, caspase
1 and caspase 5 are significantly increased in AD com-
pared to MCI and HC (p <0.05) (Fig. 2a).
Up-regulation of inflammasome-related cytokines in
LPS-primed and Aβ42−stimulated- monocytes of AD patients
Stimulation of monocytes with either LPS or Aβ42- alone
resulted in the moderate increase of IL-1β and IL-6 ex-
pression; notably LPS or Aβ42- alone were not sufficient
to trigger inflammasome assembly, as no differences were
detect in these conditions either in NLRP3 or IL-18
mRNA (Fig. 1). Once cells were activated with LPS and
Aβ42, nevertheless, both IL-1β (nFold >10) and IL-18
(nFold ≥10) mRNA was significantly increased in severe
and MILD AD compared to MCI and HC (Fig. 1). Results
obtained by single-PCR confirmed that in these experi-
mental conditions IL-1β and IL-18 mRNA (p <0.05 vs. all
other groups) is significantly increased in severe and
MILD AD, with the highest values in severe AD (Fig. 2b).
IL-33 and IL-37, two relatively novel cytokines that are
members of the IL-1 family, were analyzed as well in the
study. We found that IL-33 gene expression was greatly
increased in MCI (nFold >10) compared to AD and HC;
no significant differences, on the other hand, were ob-
served in IL-37 gene expression among groups analyzed
(Fig. 1). Single RT-PCR confirmed these results (Fig. 2c).
NLRP3 protein is significantly augmented in LPS-primed
and Aβ42−stimulated- monocytes of AD and MCI patients
The expression of NLRP3 protein, the best-characterized
protein within the inflammasome complex, was investi-
gated next by Western Blot analyses in LPS-primed and
Aβ42-stimulated-monocytes of all patients and controls.
Different NLRP3 isoforms are known: the long form
(118 KDa) is prevalent in cell lines (THP1 or Jurkat)
while the short one (NLRP3s 75 KDa) is seen in primary
immune cells [25]. Results of analyses performed on
whole-cell lysates confirmed that NLRP3s expression is
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LPS                          LPS+A A
nFold    10 
Genes AD MILD MCI HC 
NLRP1 437,2 385,2 119,3 2,3
NLRP3 1334,4 1007,1 309,7 2,9
PYCARD 28,0 19,0 3,0 2,0
CASP1 20,0 15,0 4,0 6,0
CASP5 16,0 17,0 1,2 -1,2
CASP 8 138,3 129,7 275,9 1,0
IL1 37,0 19,0 1,0 5,9
IL18 20,0 10,0 3,0 6,0
IL33 365,9 404,3 1259,0 42,6
LPS+A
Fig. 1 (See legend on next page.)
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significantly increased in severe (mean ± S.E.M.: 2.29 ±
0.35 AU), and MILD AD (1.32 ± 0.42 AU) compared to
healthy controls (0.1 ± 0.06 AU)(p = 0.023 vs. severe AD;
p = 0.0362 vs. MILD AD). NLRP3s expression was also
increased when MCI individuals (0.78 ± 0.24 AU) were
compared to HC, even if this difference did not reach
statistical significance (p = 0.081) (Fig. 3).
LPS-primed and Aβ42−stimulated monocytes that express
inflammasome proteins are significantly augmented in AD
Peripheral CD14+ monocytes that express NLRP3 or co-
express NLRP3 and PYCARD, NLRP3 and caspase 1, or
NLRP3 and caspase 8 were augmented in LPS-primed and
Aβ42−stimulated-cells of both groups of AD patients com-
pared to MCI individuals and HC. The Fluorochrome In-
hibitor of Caspases (FLICA) kit was used to analyze the
presence in cells of active caspases; in this method, once
inside the cell, the FLICA inhibitor probe binds covalently
to active caspases (p20) alone. Staining of active caspase 1
and caspase 8 inhibitors was performed using the green
fluorescent probe FAM-YVAD-FMK and FAM-LETD-
FMK respectively. Results showed that 1) CD14+/NLRP3+,
CD14+/NLRP3+/caspase1+, and CD14+/NLRP3+/Cas-
pase8+ immune cells were significantly increased in severe
AD patients alone compared to MCI and HC (p <0.05)
and 2) CD14+/NLRP3+/PYCARD +, cells were augmented
both in severe and MILD AD compared to MCI and
HC (MCI and HC vs. moderate AD p <0.05; vs. severe
AD p <0.01)(Fig. 4a).
LPS-primed and Aβ42-stimulated NLRP1-expressing
CD14 cells were significantly increased as well in
both groups of AD patients compared to MCI and
HC (p <0.05), while CD14+/NLRP1+/PYCARD + and
CD14+/NLRP1+/caspase1+ immune cells were aug-
mented, although not significantly, in AD patients
compared to other two groups. Finally, no differences
could be observed in CD14+/NLRP1+/caspase 5+ cells
(Fig. 4b). These results confirm those obtained in PCR
analyses and indicate that, even if some inflammasome
components are up regulated in MCI, fully functional
inflammasomes are not assembled in this situation.
Co-localization of inflammasome proteins in LPS-primed
and Aβ42−stimulated monocytes by confocal microscopy
analyses
Aggregation and activation of inflammasome complexes
was further analyzed by evaluating the co-localization of
NLRP3 and NLRP1 with PYCARD, caspase 1 or caspase
8 by confocal microscopy. Co-localization efficiency was
calculated using the Pearson co-localization coefficient
(PCC). Results showed a clear co-localization of NLRP3
with PYCARD, caspase 1 and caspase 8 in LPS-primed
and Aβ42-stimulated monocytes of AD patients alone;
no co-localization could be detected in untreated cells
(data not shown). In particular: 1) NLRP3/PYCARD,
NLRP1/PYCARD and NLRP3/caspase1 co-localization
was increased in both groups of AD patients compared
to HC and MCI; 2), NLRP3/caspase8 and NLRP1/cas-
pase5 co-localization was increased in severe AD alone;
and 3) NLRP1/caspase1 co-localization was seen only in
cells of MILD AD individuals. In all cases, with the ex-
ception of the NLRP1-caspase 1 complex, the highest
PCC values were detected in cells of patients with severe
AD disease (Fig. 5 and Table 1).
Inflammasome-related cytokines production in LPS-primed
and Aβ42−-stimulated - monocytes of AD patients
Aggregation of the inflammasome results in the down-
stream production of pro-inflammatory cytokines. Be-
cause FACS and confocal microscopy data indicated that
the different subunits that compose the inflammasome do
aggregate in LPS-primed and Aβ42−-stimulated- mono-
cytes of AD patients, and PCR analyses showed that
mRNA for these cytokines is increased in monocytes of
AD patients, IL-1β, IL-18, IL-33 and IL-37 were next mea-
sured. Results showed that the concentration of IL-1β, IL-
18 in supernatants was significantly increased in both
groups of AD patients compared to MCI and HC (IL-1β p
<0.05; IL-18 p <0.01)(Fig. 6a and b). CD14+/IL-1β+ cells
were significantly increased as well in MILD and severe
AD compared to MCI and HC (p <0.05)(Fig. 6a), whereas
lack of proper reagents prevented IL18-expressing cells to
be analyzed by FACS. The fact that IL-1β+ and IL-18 were
not increased in MCI is not surprising considering that in
this condition NLRPs but not PYCARD expression was
augmented, thus preventing the assembly of a functional
inflammasome; these data confirm the findings obtained
with FACS and confocal analyses.
IL-33 could not be quantified in supernatants (data
not shown), probably because the inflammatory mature
form of this cytokines is not cleaved and secreted.
Results obtained by flow-cytometry, nevertheless showed
that CD14+/IL-33+ cells were increased in MCI and in
MILD AD, with the lowest percentages of these cells
(See figure on previous page.)
Fig. 1 Messenger RNA expression levels of genes within the inflammasome pathway. Expression of 84 genes involved in the inflammasome
pathway assessed by real-time quantitative RT-PCR-array in monocytes of individuals with a diagnosis of either severe Alzheimer’s disease (AD),
moderate Alzheimer’s disease (MILD) or Mild Cognitive Impairment (MCI) and of age- and sex-matched Healthy Controls (HC). Heat maps of Log2
Fold changes are presented. Results obtained upon stimulating cells with LPS or Aβ42 alone, or upon LPS-priming followed by Aβ42 stimulation
are presented. Fold-changes >10 in the expression of LPS + Aβ42 stimulated genes of importance are summarized in the Table
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Fig. 2 mRNA expression by Real-Time PCR. Single Real-Time PCR results obtained in LPS and Aβ42 -stimulated monocytes of individuals with a
diagnosis of either severe Alzheimer’s disease (AD), moderate Alzheimer’s disease (MILD) or Mild Cognitive Impairment (MCI) and of age- and
sex-matched Healthy Controls (HC). a NLRP1, NLRP3, caspase 8, PYCARD, caspase 1 and caspase 5 are shown in panel a; IL-1β and IL-18 in panel
b and IL-33 and IL-37 in panel c. The results are shown as fold-change expression from the un-stimulated samples. Gene expression was calculated
relative to GAPDH housekeeping gene. Summary results are shown in the bar graphs. The boxes stretch from the 25 to the 75 percentile; the line
across the boxes indicates the median values; the lines stretching from the boxes indicate extreme values. Outside values are displayed as separate
points. Statistical significance is shown *(p <0.05), **(p <0.01)
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seen in severe AD (p <0.01)(Fig. 6c). Notably this cyto-
kine was shown to have a multifaceted protective role
against AD and to negatively modulate NF-kB activity,
dampening inflammation. Finally, CD14+/IL-37+ cells
were marginally increased in AD compared to MCI and
HC (Fig. 6d).
Discussion
Inflammasomes are intracellular complexes formed by the
assembly of multiple subunits that regulate the maturation
and the secretion of pro-inflammatory cytokines [2]. At
least four different inflammasomes are known; the
NLRP3, in particular, is suspected to play a role in the
pathogenesis of AD. Thus, in the APP/PSI animal model
of AD, NLRP3 up regulation induces the production of
IFN1β by microglia [14]; and, on the other hand, its defi-
ciency results in a decreased deposition of amyloid-β [24,
26–29]. We have previously shown that peripheral mono-
cytes of AD individuals are characterized by an inflamma-
tory profile and a higher surface density of TLR molecules
[30]. Further analyses performed in these same individuals
allowed us to demonstrate that these cells also express
binary complexes formed by Aβ peptides and MHC-
molecules, possibly initiating Aβ-specific acquired im-
mune reponses [31]. Herein we investigate the role of the
inflammasome in the neuroinflammation that accompan-
ies AD by analyzing peripheral immune cells of patients
with MCI or AD. Results obtained using molecular, con-
focal and cytofluorimetic analyses indicated that the
NLRP3 and NLRP1 inflammasomes are indeed activated
in AD. The assembly of functional inflammasomes in AD
was confirmed by the significantly increased amount of
the proinflammatory cytokines IL-1β and IL-18 that were
produced by LPS-primed and Aβ42−-stimulated- mono-
cytes of AD patients.
Notably, NLRP1, NLRP3 and caspase 8, but not
PYCARD were increased in individuals with a diagnosis
of MCI, a condition that is often but not always pro-
dromic to the development of AD. In this situation the
assembly of a functional inflammasome is not possible.
Consequently, neither a significant co-localization of
inflammasome subunits nor increased amount of IL-1β
and IL-18 were detected in these individuals. It is inter-
esting to observe that in MCI a partial, initial up regula-
tion of inflammasome proteins limited to NLRP proteins
is observed. Only a percentage of MCI progresses to AD;
these results thus allow the speculation that the inflamma-
some is somehow “primed” to be activated in all individ-
uals with a diagnosis of MCI. An increased transcription
of the other inflammasome components, the assembly of
the functional complex, and the production of proinflam-
matory cytokines, occurs only in some cases, possibly be-
cause of still unknown “triggering” events that act on an
“NLRP-primed” background.
NLRP3 and caspase 8 mRNA were up regulated in cells
of severe AD patients; CD14+/NLRP3+/caspase8+ cells
were increased as well in these individuals in whom the
co-localization of caspase 8 with NLRP3 was also de-
tected. Recent data showed that caspase 8 is not only an
inducer of cell apoptosis but, together with the Fas-
Associated protein with Death Domain (FADD), it inter-
acts with NLRP3. Such interaction is required for caspase
1 activation, as well as for IL-1β and IL-18 secretion [5].
Confocal analyses confirmed that caspase 8 is present in
the NLRP3 inflammasome complex, where it is involved
in the cleavage of pro caspase 1 and IL-1β. These results
support a direct role for caspase 8 in the processing of
caspase 1 [6]. Our data confirm these findings, as well as
recent results indicating that caspase 8 contributes to both
NF-kB–dependent priming and post-translational activa-
tion of the NLRP3 inflammasome [5]. Increased NLRP1
and caspase 5 mRNA levels were also detected in cells of
individuals with a diagnosis of severe AD. NLRP1 and cas-
pase 5 colocalized in CD14 cells, and higher percentages
of CD14+/NLRP1+/caspase 5+ immune cells were also
seen in these patients. These data indicate that the NLRP1
inflammasome complex is also activated in severe AD;
notably, recent results indicate that SNPs in the NLRP1
gene are associated with AD [32].
Inflammasome assembly leads to the production of
proinflammatory cytokines; IL-1β and IL-18 mRNA and
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Fig. 3 NLRP3s expression in Monocyte by Western blot: NLRP3s
protein expression assessed by western blotting in monocyte of
individuals with a diagnosis of either severe Alzheimer’s disease (AD),
moderate Alzheimer’s disease (MILD) or Mild Cognitive Impairment
(MCI) and of age- and sex-matched Healthy Controls (HC). The
same protein concentration of whole-cells lysates was loaded into
the gel, as confirmed by actin. Representative results obtained in
un-stimulated or in LPS-primed and Aβ42-stimulated monocytes are
presented in the upper panel. Quantitative evaluation (arbitrary unit,
AU) of NLRP3s expression obtained comparing band density (normalized
to actin) in un-stimulated or in LPS-primed Aβ42-stimulated monocytes
is shown in the lower panel. (N= 5, mean ± s.e.m., T test, *p <0.05).
(N=5/group, mean± S.E.M and statistical significance are shown. *(p <0.05)
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secretion were indeed significantly increased in AD.
Interestingly, incubation of cells with Aβ42 was sufficient
to induce IL-1β mRNA expression, but a significantly in-
creased production of IL-1β and IL-18 was seen in LPS-
primed and Aβ42-stimulated cells of AD patients alone.
These findings indicate that such experimental condi-
tions result in the assembly of fully functional inflamma-
somes only in cells of AD patients. Notably, transfection
of human PBMC with siRNA specific for NLRP3 and
PYCARD greatly reduced IL-1β production, confirming
that the production of this cytokine is dependent on
inflammasome assembly [33]. That IL-1β plays a role in
the pathogenesis of AD has been repeatedly shown. To
summarize: this cytokine induces a loss of phagocytic ac-
tivity by the microglia [34], stimulates the hyperphosphor-
ylation of tau protein [35] and affects synaptic plasticity.
As a consequence of these effects, IL-1β can impair learn-
ing and memory processes [36, 37]. IL-18 has been in-
volved in AD as well, even if fewer data are available.
Thus, increased amounts of IL-18 were detected in the
brain [38], plasma [39], and peripheral blood lymphocytes
of AD [40], and the expression of the IL-18R complex is
greatly augmented in peripheral blood cells of MCI and
AD individuals [41]. Finally, recent data indicate that IL-
18 directly stimulates Aβ production by human neuron-
like cells, suggesting a key role for this cytokine in the
pathogenesis of AD [42].
Two other novel cytokines, IL-33 and IL-37 were ana-
lyzed as well in this study; these cytokines are members
of the IL-1β family and are produced upon activation of
the inflammasome. Whereas no significant differences
were seen in IL-37, mRNA levels of IL-33 were in-
creased in both MILD AD and MCI compared to the
values observed in severe AD. Analysis of peripheral
CD14+/IL-33+ cells confirmed this observation, as these
cells were increased both in MCI and MILD AD com-
pared to severe AD and HC. IL-33 and IL-37 are dual
function proteins with both intra and extra-cellular
mechanisms of action as, besides being able to bind to
their cognate receptors on target cells, they can act
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intracellularly as nuclear factor. IL-33 is reduced in AD
brains [43]. This cytokine is believed to have a neuropro-
tective role secondary to the reduction of Aβ peptides
secretion [44] and the activation of the phagocytosis of
amyloid-β peptide by the microglia [45]. IL-33 also inter-
acts intracellularly with the NF-kB p65 subunit [44]; the
resulting IL-33/NF-kB p65 complex interferes with NF-
kB–dependent transcription by impeding p65-mediated
transactivation. This causes a negative modulation of
NF-kB activity, with a dampening effect on inflammation
[46]. The increase of IL-33 production in MCI and in
MILD AD could thus be seen as an attempt of the im-
mune response to reduce neuroinflammation. On the
other hand, the observation that the levels of IL-33 seen
in severe AD are comparable to those observed in eld-
erly healthy individuals suggest that the IL33-dependent
anti-inflammatory effects do not need to be activated
in the absence of the pathological alterations present
in AD.
Results herein stem from immunological analyses per-
formed in peripheral blood immune cells; a number of
data nevertheless provide evidence that the brain is in-
vaded by peripherally derived monocytes/macrophages
[47]. In murine models of Alzheimer’s disease, mice
brains are infiltrated by bone marrow-derived macro-
phages that associate with amyloid plaques and clear Aβ
deposits from the brain [48]. Our data indicate that the
CD14+ cells that are likely present in the CNS of AD
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Fig. 5 Confocal microscopy: co-localization of inflammasome proteins in CD14+ cells. Representative confocal fluorescence images (63× magnification) of
experiments (N = 5) showing the effect of LPS-priming and Aβ42-stimulation on NLRP3/PYCARD (a) and NLRP1/caspase 1 (b) co-localization in monocytes
of individuals with a diagnosis of either severe Alzheimer’s disease (AD), moderate Alzheimer’s disease (MILD) or Mild Cognitive Impairment (MCI) and of
age- and sex-matched Healthy Controls (HC). Summary results of NLRP3/PYCARD and NLRP1/caspase-1 PCC (Pearson co-localization efficiency)
are presented in (c) and (d), respectively. The boxes stretch from the 25 to the 75 percentile; the line across the boxes indicates the median
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Table 1 Co-localization coefficient of inflammasome proteins. Pearson’s co-localization coefficient (PCC) of NLRP1 and NLRP3 with
PYCARD, caspase-1, caspase-5 and caspase-8, in LPS-primed and Aβ42−stimulated CD14+ monocyte of patients with a diagnosis of
either severe or moderate (MILD) Alzheimer’s Disease (AD) and mild cognitive impairment (MCI). Result obtained in and in age-and
sex-matched healthy controls (HC) are also shown. Index reference values: PC range= −1 and +1
PCC severe AD MILD AD MCI HC
NLRP1+ PYCARD + 0.8ac (0.7-0.82) 0.8 de (0.7-0.82) 0.5ad (0.3-0.6) 0.4ce (0.3–0.5)
NLRP1+ CASPASE-1+ 0.6 (0.4-0.7) 0.8 (0.7-0.84) 0.6 (0.4-0.65) 0.5 (0.5-0.7)
NLRP1+ CASPASE-5+ 0.7bac (0.5–0.8) 0.4b (0.23-0.5) 0.3a (0.1-0.32) 0.3c (0.2-0.5)
NLRP3+ PYCARD + 0.8ac (0.6-0.82) 0.8 de (0.7-0.82) 0.6ad (0.5-0.7) 0.5ce (0.4-0.6)
NLRP3+ CASPASE-1+ 0.9bac (0.8-0.9) 0.8bde (0.5-0.8) 0.5ad (0.4-0.56) 0.3ce (0.3-0.4)
NLRP3+ CASPASE-8+ 0.8ac (0.7-0.85) 0.6 (0.5-0.72) 0.5a (0.3-0.55) 0.5c (0.3-0.6)
Median values, interquartile range and statistical significances are presented (p <0.05)
aAD vs. MCI
bAD vs. MILD AD
cAD vs. HC
dMILD AD vs. MCI
eMILD AD vs. HC
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patients can carry active inflammasome complexes. It
also has to be remembered that the role of inflammation
in AD is ambiguous. Thus, whether this phenomenon is
considered to be responsible for AD-associated neurode-
generation, an alternate hypothesis sees it as a mono-
cyte/macrophages-mediated attempt to slow down the
accumulation of Aβ plaques in the brain. Longitudinal
studies and analyses performed in animal models will be
needed to clarify this issue.
Conclusions
NLRP3 up regulation in mice or human microglia cell line
or in brain of AD patients has been previously reported
[14, 24, 49], these are nevertheless the first data showing
NLRP3 and NLRP1 inflammasome activation in Aβ stimu-
lated peripheral monocytes of individuals with a diagnosis
of AD. It will be interesting to verify whether these data
could have a prognostic and/or diagnostic value in the clin-
ical setting. In particular, the observation that some
(NLRP1, NLRP3) but not not all (PYCARD, caspase 1) of
the genes necessary for the assembly of an inflammosome
complex genes are upregulated in MCI suggests that moni-
toring the transcription rate of, e.g. PYCARD in MCI could
offer an early diagnostic tool for AD development. Migra-
tion of peripheral monocyte across the blood-brain barrier
is likely an important factor in the neuroinflammation that
accompanies Alzheimer’s disease. Very recent results
showed that nucleoside reverse transcriptase inhibitors in-
hibit the activation of the inflammasome [50]. If neuroin-
flammation is deleterious in AD, these drugs could be an
interesting tool in the treatment of this disease.
Methods
Patients and controls
Twenty individuals with a diagnosis of mild cognitive im-
pairment (MCI) and a Mini- Mental State Examination
(MMSE) score >24, 21 patients with moderate Alzheimer’s
disease (MMSE score 19–23), 19 patients with severe
Alzheimer’s disease (MMSE score <19) and 40 age-and
sex-matched healthy controls (HC) were enrolled in the
study. The clinical diagnosis of Alzheimer’s disease was
performed according to the NINCDS-ADRDA work group
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Fig. 6 IL-1β, IL-18, IL-33 and IL-37 production. IL-1β, (panel a), IL-18
(panel b), IL-33 (panel c) and IL-37 (panel d). Interleukin-1β and IL-18
production was assessed by multiplex ELISA in supernatants. CD14+/IL-
1β+, CD14+/IL-33 and CD14+/IL-37+ cells were analyzed by
flow-cytometry. In both cases, LPS-primed and Aβ42-stimulated
monocytes of individuals with a diagnosis of either severe Alzheimer’s
disease (AD), moderate Alzheimer’s disease (MILD) or Mild Cognitive
Impairment (MCI) and of age- and sex-matched Healthy Controls (HC)
were analyzed. Summary results are shown in the bar graphs. The boxes
stretch from the 25° to the 75°percentile; the line across the boxes
indicates the median values; the lines stretching from the boxes indicate
extreme values. Statistical significance is shown *(p <0.05), **(p <0.01)
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criteria [51] and the DMS IV-R [52]. All Alzheimer’s dis-
ease patients underwent complete medical and neuro-
logical evaluation, as well as laboratory analysis, and CT
scan or MRI. Additional investigations (e.g., EEG, SPECT
scan, CSF examination, etc.) were performed in some cases
to exclude reversible causes of dementia. Neuropsycho-
logical evaluation and psychometric assessment were per-
formed with a neuropsychological battery that included the
MMSE [53], Digit Span Forward and Backward, Logical
Memory and Paired Associated Words Tests, Token Test,
supra Span Corsi Block Tapping Test, Verbal Fluency
Tasks, Raven Colored Matrices, the Rey Complex Figure,
Clinical Dementia Rating Scale (CDR) [54], and the
Hachinski Ischemic Scale. Individuals with a diagnosis of
MCI were selected among subjects seen at our Memory
Disorders Outpatients Service for the diagnostic evaluation
of memory complaints without difficulties in daily activ-
ities. MCI diagnosis was based on Petersen’s criteria [55] as
follows: 1) reported cognitive decline, 2) impaired cognitive
function, 3) essentially normal functional activities, and 4)
exclusion of dementia. The healthy controls were selected
according to the SENIEUR protocol for immuno-
gerontological studies of European Community’s Con-
trol Action Program on Aging [56, 57]. The cognitive
status of HC was assessed by administration of MMSE
(score for inclusion as normal control subjects >28).
Written consent was obtained and ethical approval
was granted by the Ethics Committee of the Don C
Gnocchi Foundation in Milano, Italy.
Blood sample collection and cell separation
Fifty ml of whole blood were collected in vacutainer
tubes containing ethylenediaminetetraacetic acid (EDTA)
(Becton Dickinson & Co., Rutherford, NJ, USA). Periph-
eral blood mononuclear cells (PBMC) were separated on
lympholyte separation medium (Cedarlane, Hornby,
Ontario, CA) and washed twice in PBS at 1500 RPM for
10 min; viable leukocytes were determined using a Scep-
ter 2.0 Handheld Automated Cell Counter (Millipore,
Billerica, MA).
Cell cultures
PBMC (1 × 106/ml) were cultured in 12 well cell culture
plate (Greiner Bio-One GmbH Frickenhausen Germany)
with RPMI 1640 supplemented with 10 % human serum,
2 mM L-glutamine, and 1 % penicillin (Invitrogen Ltd,
Paisley, UK) for 2 h at 37 °C in a humidified 5 % CO2 at-
mosphere [58]. Non adhering PBMC were then washed
away and monocytes were either resuspended in medium
alone (medium), or were stimulated with: 1) 2 μg/ml Lipo-
polysaccharide (LPS) for 2 h (Sigma-Aldrich, St. Luis, MO,
USA), 2) 10 μg/ml of 1–42 amyloid-beta peptide oligomer
(Aβ42)(Sigma-Aldrich) for 24 h, or 3) primed with LPS
(2 μg/ml) for 2 h before stimulation with 10 μg/ml of Aβ42
peptide oligomer for 24 h. In all cases cells were incubated
at 37 °C in a humidified 5 % CO2 atmosphere. As it has
been repeatedly shown, LPS pre-incubation is necessary to
induce the intracellular accumulation of NLRP3 and pro-
IL-1β, thus allowing the assembly of fully functional
inflammasome complexes [13, 14, 59, 60]. For confocal mi-
croscopy analyses PBMC were cultured on chamber slide
(Lab Tek Nalge Nunc Intern. Naperville IL USA) for 2 h at
37 °C in a humidified 5 % CO2 atmosphere [58]. Non ad-
hering PBMC were then washed away and monocytes were
either resuspended in medium alone or were stimulated
with 1) 2 μg/ml LPS for 2 h (Sigma-Aldrich), 2) 10 μg/ml
of Aβ42oligomer (Sigma-Aldrich) for 24 h, or 3) primed
with LPS (2 μg/ml) for 2 h before stimulation with 10 μg/
ml of Aβ42 peptide oligomer for 24 h. In all cases cells were
incubated at 37 °C in a humidified 5 % CO2 atmosphere.
Finally monocytes on chamber slide were fixed in 4 %
paraformaldehyde in PBS for 15 min.
RNA extraction and reverse transcription
RNA was extracted from unstimulated, LPS- or Aβ42-
primed, or LPS-primed and Aβ42-stimulated-monocytes
using the acid guanidium thiocyanate–phenol–chloro-
form method. RNA was dissolved in RNase-free water
and purified from genomic DNA with RNase-free DNase
(RQ1 DNase; Promega, Madison, WI). One microgram
of RNA was reverse transcribed into first-strand cDNA
in a 20 μl final volume containing 1 μM random hexa-
nucleotide primers, 1 μM oligo dT and 200 U Moloney
murine leukemia virus reverse transcriptase (Clontech,
Palo Alto, CA). cDNA were evaluated for GAPDH ex-
pression by Real Time PCR to test RNA quality.
Inflammasome signalling pathway
The human Inflammasomes RT2 Profiler PCR Array
(Qiagen PAHS-097Z) was used to analyze gene expression
of inflammasome components and signalling pathways. In
this array a set of optimized primer assays allows the de-
tection of mRNA transcripts of 84 genes as well as five
housekeeping genes in a 96-well plate by real-time PCR.
Individual specimens were pooled according to MMSE
scores (severe AD, MILD AD, MCI, HC). cDNA from un-
stimulated cells and from cells stimulated with either LPS
or Aβ42 alone or, finally, that had been LPS-primed and
Aβ42 stimulated were grouped in different pools for PCR
arrays. Data were analyzed by the comparative Ct method
using GAPDH as the reference gene. Results are expressed
as the fold changes between LPS or Aβ42 or LPS-primed
and Aβ42 stimulated pools from each disease state and
unstimulated condition. Heat maps were generated and
genes hierarchically clustered by Euclidean distance
and single linkage using TIGR MultiExperiment Viewer
(MeV) v4.9 [61].
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Real time quantitative reverse transcription
Real Time quantitative Reverse Transcription PCR
(RQPCR) was performed on a ABI Prism 7000 instru-
ment (PE Applied Biosystems, Foster City, CA, USA)
with gene specific primers and the SybrGreen chemis-
try to confirm the gene expression changes observed by
arrays. All primers were cDNA specific and were pur-
chased from Qiagen (Venlo, PB Venlo, The Netherlands).
Specific PCR products amplification was detected using
the RT2 SYBR Green Fluor with a 25 μl final volume of
12.5 μl RT2 qPCR Mastermix (Qiagen) 10.5 μl H2O,
1.0 μl of either diluted template or 1.0 μl RT2 qPCR
Primer Assay. Results were expressed as ΔΔCt and pre-
sented as ratios between the target gene and the GAPDH
housekeeping mRNA. Experiments were run on each sub-
ject included in the study.
Western blotting
Unstimulated and LPS-primed and Aβ42 stimulated-
monocytes were washed and lysed with M-PER Mam-
malian Protein Extraction Reagent with phosphatase and
protease inhibitors (10 μl/ml, Halt™ Protease and Phosphat-
ase Inhibitor Cocktail, Thermo Scientific Inc, Rockford, IL,
USA). After protein estimation using the Bradford Assay
reagent (Bio-Rad) 20 μg of cell lysate was resolved by elec-
trophoresis on a 10 % SDS-polyacrylamide gel under redu-
cing conditions. Proteins were then transferred to PVDF
membrane by electrophoretic blotting and blocked for 1 h
in blocking buffer (Blocker BLOTTO Blocking Buffer,
Thermo Scientific). Membranes were then incubated over-
night with sheep anti-recombinant NALP3 (AF6789,
R&D Systems) or for 1 h with sheep anti beta-actin
antibody (AF4000, R&D Systems), then diluted 1:1000
in blocking buffer followed by HRP-conjugated anti-
sheep IgG (HAF016, R&D Systems). Bound antibodies
were visualized with a chemiluminescence development
reagent (LiteAblot TURBO, Euroclone, Italy) according
to the manufacturer’s instructions. Bands were imaged
in a Gel-Doc Cabinet and the density of the image was
measured. The density of each band was normalized
with beta-actin (as housekeeping protein) and for each
sample an arbitrary units (AU) value was calculated as
follows: normalized density of NLRP3 band obtained
from stimulated (LPS-primed+Aβ) monocytes/normal-
ized density of NLRP3 band obtained from unstimu-
lated monocytes.
Flow cytometry immunofluorescent staining
Unstimulated and LPS-primed and Aβ42-stimulated-
monocytes were stained with anti-CD14-PC7 (clone
RMO52, isotype mouse IgG2a, Beckman Coulter, CA
USA) mAb for 30 min at 4°. Cells were then washed,
treated with FIX and PERM Cell kit (eBioscience, San
Diego, CA, USA), and stained with anti- NLRP3-PE (clone
768319; isotype rat IgG2a R&D Systems Inc. Minneapolis
MN, USA), −NLRP1-APC (isotype rabbit polyclonal IgG
Proteintech, Chicago, IL, USA), −caspase 5-FITC (isotype
rabbit polyclonal; LifeSpan BioSciences,Inc, Seattle, WA
USA), − PYCARD-FITC (clone HASC-71; isotype mou-
seIgG1k, eBioLegend San Diego CA,USA), IL-1β FITC(-
clone 8516; isotype mouse IgG1; R&D) IL-33-APC (clone
39412 isotype rat IgG2B R&D), or IL-37-PE (clone 6A6,
isotype mouse IgG1k LSBioSciences, Inc) mAb for 30 min
at 4°. The Fluorochrome Inhibitor of Caspases (FLICA) kit
was used to analyze caspases. This kit uses a novel ap-
proach to detect active caspases. Once inside the cell, the
FLICA inhibitor probe binds covalently to the active cas-
pase (p20) alone. Staining of active caspase 1 and caspase
8 inhibitors was performed using the green fluorescent
probe FAM-YVAD-FMK and FAM-LETD-FMK respect-
ively, following the procedures suggested by the manufac-
turer (AM-FLICA, Immunochemistry, Bloomington, IN,
USA). NLRP1, caspase 5 and PYCARD were conjugated
using the Lightning-Link APC or FITC conjugation kit
(Innova Biosciences, Cambridge, UK). Cells were finally
analyzed using a Beckman-Coulter GALLIOS flow cyt-
ometer equipped with a single 15 mW argon ion laser op-
erating at 488 nm and interfaced with CXP Software 2.1.
200,000 cells were acquired and gated on CD14 expres-
sion and side scatter properties. Isotype control or single
fluorochrome-stained preparations were used for color
compensation.
Confocal microscopy analysis
Unstimulated, LPS- or Aβ42- primed, or LPS-primed and
Aβ42-stimulated-PBMC were cultured on chamber slide
(Lab Tek Nalge Nunc Intern. Naperville IL USA) for 24 h
at 37 °C. Non-adherent cells were then washed away and
monocytes were grown on chamber slides, fixed in 4 %
paraformaldehyde in PBS for 15 min, and treated for 1 h
at room temperature with FLICA staining of active cas-
pase 1 or caspase 8 using green fluorescent FAM-YVAD-
FMK probes, following the procedures suggested by the
manufacturer (AM-FLICA). Cells were then treated with
FIX and PERM Cell kit (eBioscience), and stained with PE
or APC or FITC conjugated -mAbs specific for NLRP3 or
NLRP1 and PYCARD or caspase 5 for 24 h at 4 °C. Finally
cells were fixed with paraformaldehyde 1 % for 15 min,
washed and mounted on slides using the Vectashield
Mounting Medium (Vector Laboratories, Inc, Burlingame,
CA, USA). Fluorescent images were acquired on a Leica
TCS DMRE spectral laser-scanning confocal microscope
(Leica Microsystems, Wetzlar, Germany) with the appro-
priate filters and laser (488, 633) and a 63× objective lens.
Image analysis was performed using the Leica Confocal
Software and co-localization index with ImageJ Software.
Co-localization indexes were calculated using the plug in
JACoP (Justo Another Co-localization Plugin) [62]. The
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summarized co-localization efficiency data was expressed
as Pearson correlation coefficient (PCC) as previously de-
scribed [63–65]. Briefly this coefficient measures the sig-
nificance of true co-localization. The significance test
evaluates the probability that the measured value of r
obtained from the two colours is significantly greater
than values of r that would be calculated if there were
only random overlap. The test is performed by ran-
domly scrambling the blocks of pixels (instead of indi-
vidual pixels, because each pixel’s intensity is correlated
with its neighbouring pixels) in one image, and then
measuring the correlation of this image with the other
(unscrambled) image (Costes et al.) The test produces
values in the range −1 + 1, 0 indicating that there is no
discernible correlation and −1 and +1 meaning strong
negative and positive correlations, respectively.
Cytokines in supernatants
Supernatants of unstimulated, LPS- or Aβ42- primed, or
LPS-primed and Aβ42-stimulated-PBMC were analyzed.
Interleukin-1β, IL-18 and IL-33 concentration were
measured using the Human IL-1 β (Quantikine ELISA
Kit DLB50; R&D Systems), Human IL-33 (Quantikine
ELISA KitD3300; R&D Systems), and Human IL-18
(ELISA Kit -LS-F118-1; LifeSpan BioSciences, Inc.) ac-
cording to the manufacturer’s recommendations.
Statistical analyses
Quantitative data were not normally distributed (Shapiro–
Wilk test) and are thus summarized as median and Inter-
quartile Range (IQR) (25° and 75° percentile). Comparisons
between groups were analyzed used a Kruskal-Wallis
ANOVA for each variable. Comparisons among the differ-
ent groups were made using a 2-tailed Mann-Whitney U
test performed for independent samples. Western Blot
data were normally distributed, and were summarized
as mean ± standard error. In this case, comparisons were
performed using ANOVA and unpaired Student’s t test.
Data analysis was performed using the MedCalc statistical
package (MedCalc Software bvba, Mariakerke, Belgium).
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